TB-500 and Thymosin Beta-4
TB-500 and Thymosin Beta-4 Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption Table of Contents 1. TB-500 and TB-4 — what’s in a name 2. G-actin sequestration — the foundational mechanism 3. Ce
TB-500 and Thymosin Beta-4
Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption
Table of Contents
1. TB-500 and TB-4 — what’s in a name
2. G-actin sequestration — the foundational mechanism
3. Cell migration regulation
4. Angiogenesis — TB-4’s vascular biology
5. Anti-inflammatory signalling
6. Cardiac repair evidence
7. Dermal wound healing
8. Corneal repair
9. Neural repair and neuroprotection
10. Musculoskeletal tissue repair
11. TB-500 vs full-length TB-4
12. Protocol design considerations
13. UK procurement and quality
14. Frequently asked questions
15. References
1. TB-500 and TB-4 — what’s in a name
Thymosin beta-4 (TB-4 or Tβ4) is a 43-amino-acid naturally occurring peptide encoded by the TMSB4X gene. It is expressed in nearly every mammalian cell at high intracellular concentrations (on the order of 100-500 µM), making it one of the most abundant actin-binding proteins.
TB-500 is a synthetic peptide based on the active region of TB-4 — commonly marketed as a 17-amino-acid sequence (including the acetylated N-terminal methionine and the active hexa- or heptapeptide core Ac-SDKP, and its extended active region LKKTETQ). The precise sequence sold as “TB-500” varies across suppliers; rigorous research-grade suppliers specify the exact sequence on the Certificate of Analysis.
For UK research purposes, “TB-500” is treated as a synthetic active-region analogue of TB-4 that captures the principal biological activities of the parent peptide relevant to tissue repair.
2. G-actin sequestration — the foundational mechanism
The canonical molecular function of TB-4 is binding monomeric G-actin with a 1:1 stoichiometry, sequestering it and preventing its incorporation into actin filaments (F-actin). This regulates the dynamic equilibrium between G-actin (the monomer pool) and F-actin (the polymerised cytoskeleton).
The regulatory effect of G-actin sequestration is far-reaching because actin cytoskeleton dynamics underpin:
Cell shape and polarity
Cell migration
Cell division
Membrane trafficking
Intracellular signalling
By regulating the G-actin/F-actin balance, TB-4 (and TB-500 as the active-region analogue) modulates all of these processes.
3. Cell migration regulation
Cell migration requires coordinated actin filament assembly at the leading edge and disassembly at the trailing edge. TB-4’s G-actin sequestration provides the monomeric pool from which new filaments assemble, with cofactors (profilin, formins, Arp2/3 complex) directing the polymerisation at specific cellular locations. Enhanced TB-4 availability — whether intracellular or exogenously supplied — promotes cell migration in multiple cell types: endothelial cells (angiogenesis), fibroblasts (connective tissue repair), progenitor cells (tissue regeneration), and inflammatory cells.
This cell-migration phenotype underlies much of TB-500’s observed efficacy in tissue-repair preclinical models.
4. Angiogenesis — TB-4’s vascular biology
TB-4 promotes angiogenesis via endothelial cell migration, tube formation, and endothelial progenitor cell recruitment. The mechanism is distinct from VEGFR2-mediated angiogenesis (the BPC-157 pathway) — TB-4 engages actin cytoskeleton regulation rather than direct growth factor receptor signalling. Published studies document TB-4’s angiogenic activity in multiple endothelial cell assays and in vivo vascular models.
5. Anti-inflammatory signalling
TB-4 has anti-inflammatory signalling activity across multiple pathways — modulation of inflammatory cytokine production, suppression of NF-κB pathway activation in certain contexts, and regulation of inflammatory cell migration. This contributes to TB-500’s use in preclinical models of tissue injury where inflammation is a dominant pathological driver.
6. Cardiac repair evidence
TB-4’s most developed organ-specific evidence base is in cardiac repair. Bock-Marquette et al. (2004, Nature) demonstrated that TB-4 administration after myocardial infarction (MI) in mice improves cardiac function, reduces infarct size, and promotes survival of cardiomyocytes. Subsequent work (Smart et al., Nature 2007) extended this to adult epicardial progenitor mobilisation — TB-4 reactivates embryonic epicardial cells in the adult heart, recruiting them to the damage zone.
This cardiac regenerative biology is the distinctive feature of TB-4/TB-500 relative to other research-grade tissue-repair peptides.
7. Dermal wound healing
Dermal wound healing studies show TB-500 accelerates:
Keratinocyte migration and re-epithelialisation
Fibroblast recruitment to the wound bed
Angiogenesis in the healing wound
Collagen remodelling during wound maturation
These effects have been documented across murine, porcine and rat wound healing models.
8. Corneal repair
Corneal epithelial wound healing is a well-characterised TB-4 research area, with evidence for accelerated re-epithelialisation and reduced scarring. TB-4 has been evaluated in human clinical trials for dry eye disease and corneal wound healing under the name of specific TB-4-based therapeutic formulations (distinct from the research-grade TB-500 peptide), though regulatory approvals remain limited.
9. Neural repair and neuroprotection
TB-4 preclinical neural evidence includes:
Accelerated research applications after stroke in rodent models
Neuroprotection in traumatic brain injury models
Promoted oligodendrogenesis and remyelination
Enhanced peripheral nerve repair
The mechanism in the CNS appears to involve both anti-inflammatory effects and progenitor cell recruitment, consistent with TB-4’s broader biological activity profile.
10. Musculoskeletal tissue repair
TB-500 musculoskeletal evidence spans tendon, ligament, muscle and bone. The effect sizes and replication depth vary by tissue, but the consistent direction of effect is accelerated healing with improved histological and functional outcomes. See our TB-500 UK Research Guide for the full musculoskeletal evidence summary.
11. TB-500 vs full-length TB-4
TB-500 (synthetic active-region analogue) and full-length recombinant TB-4 differ in:
Size and molecular weight: TB-500 is a shorter peptide (typically ~17 amino acids vs TB-4’s 43).
G-actin binding affinity: the full-length peptide has higher actin affinity; the active-region analogue retains biological activity but may bind actin less tightly.
Manufacturing: TB-500 is chemically synthesised; TB-4 can be recombinantly produced.
Pharmacokinetics: the two may have different stability and clearance profiles.
For most research applications, TB-500 is treated as a functional analogue of TB-4 — the convention in the research-grade peptide space.
12. Protocol design considerations
For UK research protocol design:
Dose: typical rodent doses 2-10 mg per administration, dosing weekly or twice-weekly reflecting longer half-life than BPC-157.
Route: IM or SC most common; IP in some studies.
Duration: 2-6 weeks typical for tissue-repair protocols.
Endpoint: model-specific (cardiac function, wound healing, histology, behavioural).
Controls: saline/vehicle; include an active comparator (e.g., BPC-157) for mechanism comparison studies.
Peptide quality: ≥ 98% HPLC with MS identity confirmation; batch-specific COA.
See our BPC-157 vs TB-500 comparison for route, dose and mechanism contrast guidance.
13. UK procurement and quality
UK research-grade TB-500 procurement requirements mirror the broader peptide class:
≥ 98% HPLC (≥ 99% emerging 2026 standard)
Identity confirmed by MS — crucial for TB-500 given sequence variation across suppliers
Batch-specific COA with explicit sequence disclosure
Lyophilised format, UK cold-chain dispatch
Endotoxin testing for cell/animal work
See our Research-Grade Peptides Guide for full standards detail.
14. Frequently asked questions
What is the difference between TB-500 and TB-4?
TB-4 (thymosin beta-4) is the naturally occurring 43-amino-acid peptide. TB-500 is a synthetic peptide based on the active region of TB-4, typically ~17 amino acids in length, capturing the principal biological activities of the parent molecule.
What is TB-500’s molecular mechanism?
Primarily G-actin sequestration — binding monomeric actin and regulating the G-actin/F-actin equilibrium. This underlies downstream effects on cell migration, angiogenesis, and tissue repair.
Is TB-500 stronger than BPC-157 for cardiac research?
TB-500 has a more developed preclinical cardiac evidence base than BPC-157, particularly in post-MI remodelling models. For cardiac-focused protocols, TB-500 is the primary research peptide.
Has TB-500 or TB-4 been tested in humans?
TB-4-based therapeutic formulations have been evaluated in human clinical trials for specific indications (e.g., dry eye disease), but TB-500 as the research-grade peptide is investigational and not approved for human use in the UK, EU or US.
What is TB-500’s half-life?
Longer than BPC-157 in rodent studies — consistent with weekly-to-twice-weekly dosing protocols vs BPC-157’s daily convention. Precise half-life estimates vary across studies.
How should TB-500 be dosed in rodent studies?
Typical rodent protocols use 2-10 mg per dose, administered IM or SC, weekly or twice-weekly, over 2-6 weeks for tissue-repair endpoints. Specific doses should be guided by the endpoint and model.
Can TB-500 and BPC-157 be combined?
Combination dosing has been explored but rigorous evidence for synergistic vs additive effect is limited. Factorial-design protocols are needed to resolve the question.
15. References
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012;12(1):37-51.
Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472.
Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007;445(7124):177-182.
Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010;24(7):2144-2151.
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 2010;1194:179-189.
Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res 2002;74(2):293-299.
Xiong Y, Mahmood A, Meng Y, et al. Treatment of traumatic brain injury with thymosin β4 in rats. J Neurosurg 2011;114(1):102-115.
Morris DC, Chopp M, Zhang L, Zhang ZG. Thymosin beta4: a candidate for treatment of stroke? Ann N Y Acad Sci 2010;1194:112-117.
Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev 2004;125(2):113-115.
Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999;113(3):364-368.
UK Research Cluster Hubs
TB-500 UK Research Guide
BPC-157 UK Research Guide
GLP-1 Peptides Complete Research Reference
Retatrutide UK Research Guide
Tirzepatide UK Research Guide
Research-Grade Peptides Standards Guide
UK Research Peptide Buying Guide
Disclaimer: TB-500 is an investigational peptide not approved for human use in the UK, EU or US. All products supplied by Peptides Lab UK are for licensed in vitro and ex vivo laboratory research purposes only. Not for human consumption, veterinary use, or any therapeutic application.
William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.